MedPath
HSA Approval

APO-NORTRIPTYLINE CAPSULE 25 mg

SIN09253P

APO-NORTRIPTYLINE CAPSULE 25 mg

APO-NORTRIPTYLINE CAPSULE 25 mg

March 18, 1997

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

N06AA10

nortriptyline

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

APOTEX INC

Active Ingredients

NORTRIPTYLINE HCl

25 mg

Nortriptyline

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

APO-NORTRIPTYLINE CAPSULE 25 mg - HSA Approval | MedPath